Fisher and Paykel has published its financial results for the first six months of the 2014 business year, during which it achieved record-breaking figures and double-digit growth.
The company's operating revenue for the half-year ending on September 30th 2013 came to NZ$303.9 million (151.71 million pounds), up by 14 percent year on year, while its net profit after tax grew by 34 percent to NZ$44.5 million.
“Fisher and Paykel has announced record-breaking financial results for the first six months of the 2014 business year.“
Marked improvements were achieved by the firm's two major product groups, with its respiratory and acute care and obstructive sleep apnoea divisions both seeing operating revenue improvements of 15 percent.
Underlying growth is expected to be robust for the remainder of the year, thanks to rising demand for a broad range of new products and additional applications for established offerings.
Michael Daniell, chief executive officer of Fisher and Paykel Healthcare, said: "We are pleased with the record results achieved for the half year, with both of our major product groups delivering strong growth."
The company raised its financial guidance for the current business year in August 2013, due to its better-than-expected recent growth rate.See all the latest jobs in Medical Devices